Abstract Number: 0733 • ACR Convergence 2020
Practice Patterns for Tapering Medications in the Treatment of JIA-associated Uveitis
Background/Purpose: Juvenile idiopathic arthritis associated uveitis (JIAU) is the most common extra-articular manifestation of JIA, and occurs in approximately 10% of affected children. Although there…Abstract Number: 1682 • ACR Convergence 2020
Goal-Setting Improves Transition Readiness in Adolescents with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased morbidity, mortality and loss to follow-up. This is largely due to a…Abstract Number: 0714 • ACR Convergence 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…Abstract Number: 0734 • ACR Convergence 2020
Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: Down syndrome-associated arthritis (DA) is under-recognized with delay in diagnosis (1). The majority of those with DA present with polyarticular, rheumatoid factor (RF) and…Abstract Number: 1683 • ACR Convergence 2020
Ready or Not? Measuring Readiness for Transition to Adult Care in Adolescents with JIA & jSLE
Background/Purpose: Transitioning from pediatric to adult care represents a particularly vulnerable period among patients with JIA and jSLE. The shift to adult care is often…Abstract Number: 0715 • ACR Convergence 2020
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept
Background/Purpose: Effectiveness of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label Phase III international study (NCT01844518). Here we assess…Abstract Number: 1148 • ACR Convergence 2020
The SHARE Recommendations on Diagnosis and Treatment of Systemic JIA
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex auto-inflammatory disease with significant morbidity including fever, rash, serositis and articular problems. With the availability…Abstract Number: 1950 • ACR Convergence 2020
Elevated Serum Gasdermin D N-terminal Implicates Macrophage Pyroptosis in Adult-onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Elevation of serum IL-18 in adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA) suggests involvement of one or more inflammasome in these…Abstract Number: 0716 • ACR Convergence 2020
Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study
Background/Purpose: Different dosing strategies of adalimumab and etanercept have been used over the past decade in the treatment of juvenile idiopathic arthritis (JIA). With regards…Abstract Number: 1149 • ACR Convergence 2020
Risk Score of Macrophage Activation Syndrome (MAS) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA)
Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of Systemic Juvenile Idiopathic Arthritis (sJIA) with a significant mortality. A score that identify sJIA…Abstract Number: 1983 • ACR Convergence 2020
Trajectories of Disease Activity in Patients with Newly Diagnosed Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: To describe data-derived 2-year trajectories of disease activity in patients with recently diagnosed juvenile idiopathic arthritis (JIA) as measured by the clinical Juvenile Arthritis…Abstract Number: 2788 • 2013 ACR/ARHP Annual Meeting
Reliability and Responsivenss Of The Standardized Universal Pain Evaluations For Rheumatology Providers For Children and Youth (SUPER-KIDZ)
Background/Purpose: Pain is the most common symptom in children and youth with juvenile idiopathic arthritis (JIA), however, currently there is no comprehensive validated pain measure…
- « Previous Page
- 1
- …
- 18
- 19
- 20